Researchers have also found that OC use may reduce the risk of endometrial cancer. Results of the Cancer and Steroid Hormone Study support previous reports that combination OC use can avert the development of endometrial cancer. The study found that using combination OCs for at least 1 year reduces the risk of developing endometrial cancer to half of that seen for women who never took birth control pills. Additionally, the beneficial effect of OC use appears to persist at least 15 years after OC users stop taking birth control pills. Other studies have found that taking combination OCs for less than 1 year gives no reduction in risk of endometrial cancer and that the longer the OC use, the lower the risk.
The reduction in risk of ovarian and endometrial cancers from OC use does not apply to the sequential type of pill, in which each monthly cycle contains 16 estrogen pills followed by 5 estrogen-plus-progesterone pills. (Sequential OCs were taken off the market in 1976, so few women have been exposed to them.) Researchers believe OCs reduce cancer risk only when the estrogen content of birth control pills is balanced by progestogen in the same pill.
Previous
page
Oral
Contraceptives and Cancer Risk
Next
page
Reprinted from the National Cancer Institute, National Institutes of Health
More About CancerandContraceptives
